Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1255067 | 1.00 | GRIN1 (0.50) | GRIN1GRIN2AGRIN2BHSD11B1GRM1 | |
| SCHEMBL1255604 | 1.00 | GRIN1 (0.50) | GRIN1GRIN2AGRIN2BHSD11B1GRM1 | |
| SCHEMBL1256110 | 1.00 | GRIN1 (0.50) | GRIN1GRIN2AGRIN2BHSD11B1GRM1 | |
| SCHEMBL1255555 | 0.98 | GRIN1 (0.47) | GRIN1GRIN2AGRIN2BHSD11B1GRM1 | |
| SCHEMBL24608783 | 0.95 | GRIN1 (0.44) | GRIN1GRIN2AGRIN2BHSD11B1OPRM1 | |
| SCHEMBL4121266 | 0.91 | GRIN1 (0.42) | GRIN1GRIN2AGRIN2BHSD11B1OPRM1 | |
| SCHEMBL31114034 | 0.83 | VNN1 (0.38) | GRIN1GRIN2AGRIN2BOPRM1OPRD1 | |
| SCHEMBL28800681 | 0.79 | GRIN1 (0.36) | GRIN1GRIN2AGRIN2BHSD11B1OPRM1 | |
| SCHEMBL28272447 | 0.78 | OPRM1 (0.51) | OPRM1OPRD1OPRK1 | |
| SCHEMBL30825707 | 0.75 | GRIN1 (0.58) | GRIN1GRIN2AGRIN2BHSD11B1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149717-A1 | Functionalized polymers | BRIDGESTONE CORPORATION (JP) | 2007-06-28 | — | — | US | claimed |
| US-7879952-B2 | Functionalized polymers | BRIDGESTONE CORPORATION (JP) | 2011-02-01 | — | — | US | disclosed |
| EP-1803740-B1 | Method for preparing functionalized polymers | BRIDGESTONE CORP (JP) | 2009-03-18 | — | — | EP | disclosed |
| EP-1803740-A1 | Functionalized polymers | Bridgestone Corporation (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-20070149717-A1 | Functionalized polymers | BRIDGESTONE CORPORATION (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1501800-A1 | BOMBESIN ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003092670-A1 | BOMBESIN ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | GRIN1 780/4885GRIN2A 1010/4885GRIN2B 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.